Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States-Reference-Cited by-同舟云学术

Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States

Published:2021-06 Issue: Volume:6 Page:100177
ISSN:2666-6677
Container-title:American Journal of Preventive Cardiology
language:en
Short-container-title:American Journal of Preventive Cardiology

Author:

Baum Seth J.,Rane Pallavi B.,Nunna Sasikiran,Habib Mohdhar,Philip Kiran,Sun Kainan,Wang Xin,Wade Rolin L.^ORCID

Funder

Amgen Inc

Publisher

Elsevier BV

Reference30 articles.

1. Heart disease and stroke statistics-2017 update: a report from the American Heart Association;Benjamin;Circulation,2017

2. American Heart Association & American Stroke Association. Cardiovascular Disease: a costly burden for America — projections through 2035. https://healthmetrics.heart.org/wp-content/uploads/2017/10/Cardiovascular-Disease-A-Costly-Burden.pdf. Accessed November 2019.

3. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study;Verschuren;JAMA,1995

4. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease;Pekkanen;N Engl J Med,1990

5. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials;Baigent;Lancet,2010

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of PCSK9 inhibitor (evolocumab) in patients with non-ST segment elevation acute coronary syndrome and non-culprit artery critical lesions: a randomised controlled trial protocol (SPECIAL study);BMJ Open;2024-07

2. Geographic variation in disease burden among patients with severe persistent asthma in the United States;Annals of Allergy, Asthma & Immunology;2023-12

3. Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum;Journal of the American Heart Association;2023-06-06

4. Bempedoic Acid for Lipid Management in the Indian Population: An Expert Opinion;Cureus;2023-02-24

5. Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association;Circulation;2023-02-21